Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arry-797. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 known ✓ | Q16539 | 3/20 | 1.00 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 3/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 3/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.36 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arry-797 SCHEMBL31046796 | 1.00 | MAPK14 (1.00) | MAPK14BRD4ACKR3CDK2CDK1 | |
| Arry-797 SCHEMBL29349798 | 1.00 | MAPK14 (1.00) | MAPK14BRD4ACKR3CDK2CDK1 | |
| Arry-797 SCHEMBL29351662 | 1.00 | MAPK14 (1.00) | MAPK14BRD4ACKR3CDK2CDK1 | |
| SCHEMBL31371686 | 0.92 | MAPK14 (0.85) | MAPK14BRD4ACKR3CDK2CDK1 | |
| SCHEMBL31371552 | 0.90 | MAPK14 (0.81) | MAPK14CDK2CDK1HTR2AHTR2C | |
| SCHEMBL2443328 | 0.90 | MAPK14 (0.81) | MAPK14CDK2CDK1HTR2AHTR2C | |
| SCHEMBL15034375 | 0.90 | MAPK14 (0.81) | MAPK14HTR2AHTR2CMETKDR | |
| SCHEMBL12329316 | 0.88 | MAPK14 (0.79) | MAPK14BRD4HTR2AHTR2CALDH1A1 | |
| SCHEMBL13180094 | 0.88 | MAPK14 (0.79) | MAPK14BRD4HTR2AHTR2CALDH1A1 | |
| SCHEMBL2448270 | 0.87 | MAPK14 (0.77) | MAPK14BRD4HTR2AHTR2CMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263803-A1 | METHODS OF PREVENTING OR TREATING COVID-19 AND RELATED VIRAL DISEASES OR DISORDERS | KINARUS AG (CH) | 2023-08-24 | — | — | US | disclosed |
| US-20230257743-A1 | USE OF P38 INHIBITORS TO REDUCE EXPRESSION OF DUX4 | FULCRUM THERAPEUTICS INC (US) | 2023-08-17 | — | — | US | disclosed |
| EP-4159212-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | Fulcrum Therapeutics, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-11576916-B2 | Methods of preventing or treating ophthalmic diseases | KINARUS AG (CH) | 2023-02-14 | — | — | US | disclosed |
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-05-05 | — | — | US | disclosed |
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | FULCRUM THERAPEUTICS INC (US) | 2022-05-05 | — | — | US | disclosed |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2022-04-05 | — | — | US | disclosed |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | Fulcrum Therapeutics, Inc. (US) | 2022-04-05 | — | — | US | disclosed |
| US-11154543-B2 | P38 MAP kinase inhibitors for wound healing | THE SCHEPENS EYE RESEARCH INSTITUTE, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| WO-2021202990-A2 | METHODS FOR THE TREATMENT OF BETACORONAVIRUS INFECTIONS | TEPPER, Mark, Allan (US) | 2021-10-07 | — | — | WO | disclosed |
| US-20160346408-A1 | IRON STABILIZED MICELLES AS MAGNETIC CONTRAST AGENTS | INTEZYNE TECHNOLOGIES | 2016-12-01 | — | — | US | disclosed |
| WO-2016191549-A1 | IRON STABILIZED MICELLES AS MAGNETIC CONTRAST AGENTS | INTEZYNE TECHNOLOGIES (US) | 2016-12-01 | — | — | WO | disclosed |
| US-20160264732-A1 | BLOCK COPOLYMERS FOR STABLE MICELLES | INTEZYNE TECHNOLOGIES, INC. | 2016-09-15 | — | — | US | disclosed |
| US-20140127271-A1 | BLOCK COPOLYMERS FOR STABLE MICELLES | INTEZYNE TECHNOLOGIES, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140114051-A1 | BLOCK COPOLYMERS FOR STABLE MICELLES | INTEZYNE TECHNOLOGIES, INC. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20140113879-A1 | BLOCK COPOLYMERS FOR STABLE MICELLES | INTEZYNE TECHNOLOGIES, INC. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20120027752-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20110124627-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110098248-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133704-A1 | P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885BRD4 1366/4885ACKR3 2940/4885 |
| US-20160346408-A1 | IRON STABILIZED MICELLES AS MAGNETIC CONTRAST AGENTS | SLC40A1, TFRC, ABCB7 | MAPK14 3913/4885BRD4 2970/4885ACKR3 1469/4885 |
| US-20110124627-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR6, TLR1 | MAPK14 1690/4885BRD4 829/4885ACKR3 356/4885 |
| US-11154543-B2 | P38 MAP kinase inhibitors for wound healing | MAPK1, MMP1, MAP3K1 | MAPK14 44/4885BRD4 1260/4885ACKR3 400/4885 |
| US-20120027752-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | MAPK14 2405/4885BRD4 2602/4885ACKR3 2590/4885 |
| US-20120003215-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | MAPK14 1742/4885BRD4 2021/4885ACKR3 682/4885 |
| US-11576916-B2 | Methods of preventing or treating ophthalmic diseases | PPARA, PPARG, PPARD | MAPK14 119/4885BRD4 2356/4885ACKR3 409/4885 |
| US-20140127271-A1 | BLOCK COPOLYMERS FOR STABLE MICELLES | ABCB4, CLTB, EPHA2 | MAPK14 3958/4885BRD4 1401/4885ACKR3 2390/4885 |
| US-20230263803-A1 | METHODS OF PREVENTING OR TREATING COVID-19 AND RELATED VIRAL DISEASES OR DISORDERS | PPARA, PPARD, PPARG | MAPK14 85/4885BRD4 365/4885ACKR3 337/4885 |
| US-20140114051-A1 | BLOCK COPOLYMERS FOR STABLE MICELLES | ABCB4, CLTB, EPHA2 | MAPK14 3958/4885BRD4 1401/4885ACKR3 2390/4885 |
| US-20160264732-A1 | BLOCK COPOLYMERS FOR STABLE MICELLES | ABCB4, CLTB, EPHA2 | MAPK14 3958/4885BRD4 1401/4885ACKR3 2390/4885 |
| US-20110098248-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR6, TLR1 | MAPK14 1690/4885BRD4 829/4885ACKR3 356/4885 |
| US-11291659-B2 | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD | ZFX, TBL1XR1, TRIM28 | MAPK14 191/4885BRD4 1366/4885ACKR3 2940/4885 |
| US-20140113879-A1 | BLOCK COPOLYMERS FOR STABLE MICELLES | ABCB4, CLTB, EPHA2 | MAPK14 3958/4885BRD4 1401/4885ACKR3 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.